CHMP recommend market authorisation for Dapivirine Vaginal Ring 25 mg

This vaginal delivery system incorporating dapivirine (a non-nucleoside inhibitor of HIV-1 reverse transcriptase), is intended to be licenced for reducing the risk of HIV-1 infection during sexual intercourse. It is intended exclusively for markets outside the European Union.


European Medicines Agency